In financial news, United Therapeutics Corporation (NASDAQ: UTHR) added more than 30% on the heels of FDA approval of its pulmonary arterial hypertension (PAH), Orenitram.
Orenitram is administered orally for PAH and smallcapnetwork.com reported that investors should wait it out before buying and selling the stock. Other ways to check the stock performance is to check how rivals are doing on the SPDR S&P Biotech ETF (NYSEARCA: XBI) or iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB).
Orenitram was developed in collaboration with Supernus Pharmaceuticals and UTHR will pay Supernus part of the drug's milestone payments along with royalties from commercializing the drug globally. Incidentally, Supernus gained almost 20% before trading, reported 4-trading.com.
Despite a high of 4885, up 30.36% on Monday, UTHR was trading down 1.45% by 1pm Tuesday. However, the dip is expected to be temporary.
The technical analysis reveals an increase in share value in 2014 and 2015.
Source: Smallcap Network
WKRB News and Analysis reported Ladenburg Thalmann as upgrading UTHR to a buy rating. The upward trend in rating comes after a 'neutral' label by the analyst firm. The rating was announced in a research memo on Monday, according to The Fly On The Wall.com. According to Ladenburg, the price per share for UTHR is anticipated to reach $138 before leveling off.
UTHR was at a 52 week low at $51.38 along with a high of $115.48 for the same period of time. UTHR has a market cap of $5.75 billion with a P/E ratio of 15.96. The biotech firm posted earnings of $2.98 a share in Q4. Analyst estimates were pegged lower at $1.59, making the stock $1.39 higher.
For the quarter, UTHR revenues added to $302.20 million, while analyst estimates for the company tagged at $279.02 million. It looks like UTHR is enjoying its success, posting $2.82 earnings per stock.
